ALK and squamous cell lung carcinoma: Patients with de novo MET amplifications showed the reduced response to the treatment with receptor tyrosine kinases TKI [10], while ALK negative squamous cell lung cancer patients with de novo MET amplifications showed major partial response to a dual MET/ALK inhibitor [11].